** Shares of telehealth platform Mangoceuticals MGRX.O rise 43% to 51 cents premarket
** Co says its new $99/month injectable testosterone therapy plan saw sales jump 336% month‑over‑month since mid‑December
** MGRX says it also cut its customer acquisition costs by more than half
** Mangoceuticals expects testosterone therapy to become its main growth driver
** In 2025, MGRX plunged 70%
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.